IRLAB is granted additional patent for drug candidate mesdopetam
IRLAB is granted additional patent for drug candidate mesdopetam that expands its patent protection
Gothenburg, Sweden, September 4, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project.
“The already strong patent protection for mesdopetam is now expanded with a patent, EP3976581B1, which protects the active pharmaceutical ingredient of mesdopetam used in clinical development. With the extended protection, there is potential to extend market exclusivity for mesdopetam right up to the early 2040s, which is incredibly positive for the value of mesdopetam,” said Kristina Torfgård, CEO of IRLAB.
Mesdopetam has a vast clinical potential for unmet medical needs in Parkinson’s disease. The drug candidate is intended to treat people with Parkinson’s who develop levodopa induced dyskinesias (PD-LIDs), which is more than 30 percent of all people living with Parkinson’s. This equates to more than 1.5 million affected individuals in the eight major markets worldwide.
Mesdopetam has previously been granted a family of substance patents in all major markets worldwide. The newly approved patent covers a salt of mesdopetam which is used in the formulations in the ongoing clinical development. The patent expires in 2040. With the potential grant of a supplementary protection certificate (SPC) exclusivity can reach into the early 2040s.
Latest Posts
- Ground Up: Kids Foot Locker Boys’ and Girls’ New Releases
April 14, 2026 | Fashion, Lifestyle, World - Tendo Marketplace Hits One Million Vouchers Purchased, Establishing the Standard for Price-Transparent, High-Quality Care
April 14, 2026 | Business, Press Release, World - “Resolute Countermeasures in Our Cards,” Says China If US Imposes Tariffs
April 14, 2026 | Breaking News, World - Stratbeans and Articulate Hosted Exclusive Leadership Event in New Delhi to Accelerate AI-Driven Workplace Learning
April 14, 2026 | AI & ML, Breaking News, Business - Meta to Overtake Google in Global Digital Ad Revenue by 2026, Says eMarketer
April 14, 2026 | Breaking News, Business, World - North Korea Fires Cruise and Anti-Warship Missiles in Naval Drill from Choe Hyon
April 14, 2026 | Breaking News, World - NATO Allies Refuse to Join US Blockade Plan in Strait of Hormuz
April 14, 2026 | Breaking News, Politics, World - Amid the Blockage of Iranian Ports, United States Considering Fresh Round of Talks as Ceasefire Deadline Draws Closer
April 14, 2026 | Breaking News, Politics, World - Amid Rising Tensions, United States Begins Blockade of Iranian Ports to Pressurize Iran for Reopening the Strait of Hormuz
April 14, 2026 | Breaking News, Politics, World - Low Intensity Earthquake Jolts Jammu Kashmir’s Doda, No Damage Reported
April 14, 2026 | Breaking News, Doda, Jammu Kashmir